PDL BioPharma Completes Regular Quarterly Dividend Payment
(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)
About
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit www.pdl.com.
NOTE:
SOURCE
News Provided by Acquire Media